RSC Advances



View Article Online

View Journal | View Issue

PAPER

Check for updates

Cite this: RSC Adv., 2017, 7, 32952

Received 1st April 2017 Accepted 22nd June 2017 DOI: 10.1039/c7ra03756b rsc.li/rsc-advances

1. Introduction

The bone is a dynamic tissue that undergoes processes including bone formation and resorption.^{1,2} The balance between bone formation and bone resorption is needed to maintain bone metabolism.³ An imbalance between these processes leads to a series of metabolic bone diseases, such as osteoporosis and osteomalacias.^{4–7} Various markers of bone formation or resorption are used as a measurement of metabolic bone diseases.⁸ Among these markers, bone alkaline phosphatase (BAP) is often used in clinical practice to diagnose and monitor the overall metabolic bone disease.^{9–11} The serum BAP level is useful for evaluating patients with primary hypoparathyroidism and chronic renal failure.^{12,13}

Considering its importance, many methods have been developed for the detection of BAP, such as phenylalanine inhibition technique,¹⁴ heat inactivation technique,^{14,15} high-performance liquid chromatography,¹⁶ wheat germ lectin precipitation,¹⁷ electrophoresis,¹⁸ spectrophotometric immunoassay,³ and ELISA.¹⁷ Although these methods are sensitive, specific, and stable, they require time-consuming procedures,

Fluorescent microsphere immunochromatographic assays for detecting bone alkaline phosphatase based on biolayer interferometry-selected antibody[†]

Miao Liu, 回^a Li-Feng Zeng,^b Ya-Jie Yang,^a Li-Ming Hu^a and Wei-Hua Lai^{*a}

Bone alkaline phosphatase (BAP) is commonly used as a clinical marker for diagnosing and monitoring overall metabolic bone disease. In this study, a convenient, reliable, highly sensitive, and competitive fluorescent microsphere-lateral flow immunochromatographic assay (FM-LFIA) was developed for the quantitative detection of BAP for the first time. The antibody (ab17272) with the minimum equilibrium dissociation constant (K_D , $K_D = 1.503 \times 10^{-8}$ M) used in FM-LFIA was selected by the biolayer interferometry system. Various parameters that influence the FM-LFIA were optimized. Under the optimized conditions, the limit of detection for BAP was 0.1 ng mL⁻¹ within 15 min with a good linear range of 0.1 ng mL⁻¹ to 250.0 ng mL⁻¹. The average recoveries for intra- and inter-assays ranged from 98.6% to 103.8% and 92.4% to 111.5% with corresponding CVs of 6.7% to 8.5% and 4.6% to 9.3%, respectively. The test strips showed satisfactory stability through an accelerated aging test at 60 °C for 6 days. Owing to its high sensitivity and simplicity, FM-LFIA can be easily used to rapidly detect BAP.

and skilled operators, which are unsuitable for the rapid and convenient clinical detection of BAP.

Lateral flow immunochromatographic assay (LFIA)¹⁹ is a rapid analytical technique with several advantages such as simplicity, speediness, and sensitiveness. The technique combines immunochromatographic procedure, label technique, and antigen-antibody properties to provide rapid detection of various analytes in different field, such as human chorionic gonadotropin (HCG) detection in biomedicine,20 pathogens in food safety,²¹ and metal ions in environmental monitoring.²² In the LFIA, labels lay the foundation for improving limit of detection (LOD) because of their unique properties, such as optical absorption, fluorescence spectra, and magnetic properties. Colloidal gold (CG)23,24 is considered as one of the most widely used optical label in the LFIA. The CG has a vivid red color for qualitative detection by naked eve or quantitative detection by strip reader.25 However, colloidal goldlateral flow immunochromatographic assay (CG-LFIA) shows serious limitations when high sensitivity is needed. Various novel labels, including magnetic nanoparticles,^{26,27} quantum dots,28,29 and fluorescent microspheres (FMs)30 are recently used in LFIA to improve LOD.

FMs are polystyrene materials that contain dyes in the interior of the bead, thereby producing a stable configuration, unique luminescent properties. Because of these properties, FMs have already been used as label to detect analytes in food safety³¹ and medical diagnostics.³² Comparative evaluations between FMs and CG in the LFIA have been reported, the results

^aState Key Laboratory of Food Science and Technology, Nanchang University, 235 Nanjing East Road, Nanchang 330047, China. E-mail: talktolaiwh@163.com; Fax: +86 791 88333708; Tel: +86 13879178802

^bDepartment of Clinical Laboratory, Jiangxi Provincial People's Hospital, Nanchang 330006, China

[†] Electronic supplementary information (ESI) available. See DOI: 10.1039/c7ra03756b

showed that the FM-LFIA has advantages over CG-LFIA in terms of sensitivity, coefficient of variation (CV), and antibody needed.³³ Herein, FMs were used as the label in LFIA for BAP detection in this study.

Biolayer interferometry (BLI)^{34,35} is a technique that analyzes the changes in an interference pattern generated from the visible light that is reflected from the two surfaces. BLI is commonly used as the tool to measure and evaluate the binding affinity between biomolecules.^{35,36} In this study, a novel competitive FM-LFIA was first developed for the rapid detection of BAP concentration. BLI was used to select the anti-BAP antibody with highest binding affinity to BAP.

2. Experimental section

2.1 Reagents

The fluorescein isothiocyanate FMs (1%, solid content, w/v; excitation = 470 nm, emission = 525 nm) were purchased from Merck Company (Darmstadt, Germany). BAP human antigen was provided by Beijing Zhongsheng Jinyu Diagnosis Technology Co., Ltd. (Beijing, China). Mouse anti-human BAP monoclonal antibody (mAb, ab17272) and sheep anti-human BAP polyclonal antibody (pAb, ab68716) were obtained from Abcam Company (Cambridge, UK). Sheep anti-human BAP pAb (P4071-11B) was obtained from US Biological Company (Santiago, US). Sheep anti-human BAP pAb (0578G) was purchased from AbD Serotec Company (Oxford, UK). Sheep anti-human BAP pAb (55816) was purchased from Chemtura Corporation (New York, US). Rabbit anti-human BAP pAb (Tu3) was prepared in our laboratory. Goat anti-mouse IgG was obtained from Beijing Zhongshan Biotechnology Inc. (Beijing, China). Streptavidin-coated sensor was provided by Pall ForteBio Llc. (California, USA). Nitrocellulose membrane (NC membrane) was supplied by Millipore (Bendford, MA, USA). Polyvinylchloride backing pad, absorbent pad, sample pad, and conjugate pad were purchased from Shanghai Kinbio Tech. Co., Ltd. (Shanghai, China). Prealbumin (PA) was provided by GenWay Biotech, Inc. (San Diego, USA). Artificial serum was obtained from Huzhou InnoReagents Co., Ltd. (Zhejiang, China) Intestinal mucosa alkaline phosphatase (IALP), human placental alkaline phosphatase (PALP), hemoglobin (HGB), albumin (ALB) from human serum, 2-(N-morpholino)ethanesulfonic acid (MES), N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC), and bovine serum albumin (BSA) were obtained from Sigma (St. Louis, MO, USA). Other reagents were of analytical grade and purchased from Sinopharm Chemical Corp. (Shanghai, China).

2.2 Apparatus

The F-380 fluorescence spectrophotometer was supplied by Tianjin Gangdong Sci. &Tech Development Co., Ltd. (Tianjin, China). The fluorescence strip reader (excitation = 470 nm, emission = 525 nm) was obtained from Suzhou Helmen Precision Instrument Co., Ltd. (Suzhou, China). The Multiskan spectrum microplate reader was purchased from Thermo Fisher Scientific Inc. (Massachusetts, USA). BioDot XYZ platform combined with a motion controller, BioJet Quanti3000k dispenser, and AirJet Quanti3000k dispenser were purchased from BioDot (Irvine, CA, USA). Vacuum drying oven was obtained from Shanghai Fuma Test Equipment Co., Ltd. (Shanghai, China). The automatic guillotine cutter was purchased from Hangzhou Fenghang Technology Co., Ltd. (Hangzhou, China). The BLItz® system was provided by Pall ForteBio Llc. (California, USA).

2.3 Antibody binding kinetics analysis

In this system, the binding affinity between BAP and six anti-BAP antibodies (anti-BAP Abs): ab17272, Tu3, ab68716, 0578G, 55816, and 11B was measured by BLI using a BLItz® System. In a typical BLI experiment, each assay was involved in two committed steps: an association step where the specific binding transpired and a dissociation step where the bound antibody was removed (Fig. S1[†]). The assay was adapted from previous literature.³⁵ Briefly, 4 µL of biotinylated BAP (25 µg mL^{-1}) were pre-immobilized on the tip surface of streptavidincoated sensors in phosphate buffer saline (PBS) for 120 s. Unbound biotinylated BAP were removed from the surface of the sensors by incubation in PBS buffer for 60 s. Next, the streptavidin-coated sensors containing immobilized biotinylated BAP were incubated with 4 µL of increasing concentrations (6, 12, 25, and 50 μ g mL⁻¹) of anti-BAP Abs for 300 s (association). In this step, the binding interaction of the anti-BAP Abs to the immobilized BAP was measured. After association step, the sensors were dipped into PBS buffer without anti-BAP Abs for 300 s, and the bound anti-BAP Abs were allowed to come off the BAP (dissociation). The binding response was measured in real time on a sensorgram. The association constant (on-rate, Kon), dissociation constant (offrate, K_{off}), and equilibrium dissociation constant $(K_{off}/K_{on}, K_{D})$ were calculated by the built-in BLItz software as a 1 : 1 binding model (the relationship between K_{on} , K_{off} , K_{D} , and 1:1binding model are shown in the ESI[†]).

2.4 Preparation and characterizations of FM-mAb conjugates

FM-mAb conjugates were prepared according to a previous paper:³⁷ 0.15 mg FMs and 15 μ L of freshly prepared aqueous solution of EDC were slowly added to 3.0 mL of 0.05 M MES buffer (pH = 5.0, 6.0, 7.0, 8.0, 9.0). After 1 min sonication, 15 μ L of anti-BAP mAb (10, 20, 30, and 50 μ g mg⁻¹) was drop-wise added. The solution was incubated at room temperature for 2 h and then blocked with 300 μ L of 10% BSA (w/v) for 30 min. The mixture was centrifuged at 9000 rpm for 10 min. The final FM-mAb conjugates were dissolved in 300 μ L of solution containing 0.02 M Na₂HPO₄ (pH 5.5), 5% sucrose (w/v), 3% trehalose (w/v), 0.1% NaN₃, 1% BSA (w/v), and 1% Tween-20 (v/v). Resuspended FM-mAb conjugates were stored at 4 °C in the dark for further use. FMs and FM-mAb conjugates were analyzed using the F-380 fluorescence spectrophotometer and Multiskan spectrum microplate reader.

2.5 Preparation of the FM-LFIA test strip

Fig. 1A shows the structure of FM-LFIA strip, which is composed of sample pad, conjugate pad, nitrocellulose membrane (NC membrane), and absorbent pad. The sample pad was soaked for 3 min with 20 mM phosphate buffer containing 0.5% PVP (w/v), 3% sucrose, 1% BSA, 0.5% Tween-20 (v/v), and 0.1% NaN₃.^{33,38} The sample pad was dried at 60 °C for 2 h. The conjugate pad was pretreated with 20 mM phosphate buffer with 1% BSA, 0.5% Tween-20 (v/v), and 0.1% NaN₃ and was dried at 37 °C for 12 h. BAP (1.0, 2.0, and 4.0 mg mL⁻¹) and goat anti-mouse IgG (0.10, 0.25, and 0.50 mg mL⁻¹) were subsequently sprayed onto the NC membrane as the test line (T line) and control line (C line), respectively.

2.6 Immunoassay procedure

As shown in Fig. 1B, the immunoassay procedure was performed as follows: FM-mAb conjugates (1.0, 2.0, and 3.0 μ L) and 100 μ L of specimens diluted by MES buffer were added into the ELISA well and incubated for 3 min. Subsequently, the complex solution was pipetted to the sample pad of the FM-LFIA test strip. After 15 min, the FM-LFIA test strip was placed in the fluorescence strip reader. The fluorescence intensity of the T line (FI_T), fluorescence intensity of the C line (FI_C), and the FI_T/ FI_C ratio were recorded with the fluorescence strip reader. The results of the T line and C line could be also observed by naked eye under a UV light with the excitation wavelength of 470 nm. When there were no BAP in the specimens (negative), all FMmAb conjugates moved along the NC membrane by capillary and were captured by BAP immobilized on the T line, which caused the highest intensity of fluorescence. Once the specimens contain BAP (positive), BAP would react with its corresponding FM-mAb conjugates in the ELISA well. Later, the un-reacted FM-mAb conjugates were captured by BAP immobilized on the T line, which lead to fluorescence intensity on the T line changing from strong to weak with increasing concentration of BAP. The FM-mAb conjugates should be captured by goat anti-mouse IgG on the C line regardless of the presence of BAP (Fig. 1C).

2.7 Immunological kinetics analysis of the test strip

The kinetic analysis of FM-mAb conjugates and antigen (BAP on the T line and goat anti-mouse IgG on the C line) interaction was conducted as follows: 2.0 μ L of FM-mAb conjugates and 100 μ L of specimens (0, 5, 30, and 100 ng mL⁻¹) were added into the ELISA well and incubated for 3 min. The FI_T and FI_C were recorded every 1 min for 35 min. The kinetics reaction curve between the FM-mAb conjugates and the BAP on the T line, as well as those of the FM-mAb conjugates and the goat antimouse IgG on the C line, were established by plotting the FI_T/FI_C against the immunoreaction time.

2.8 Quantitative standard curve of the FM-LFIA test strip

The standard BAP solutions were diluted to final concentrations of 0.000, 0.005, 0.050, 0.100, 0.500, 5.000, 10.000, 100.000, 250.000, and 500.000 ng mL⁻¹ in artificial serum and were detected by the FM-LFIA test strip. The FI_T/FI_C ratios between the negative and positive samples were defined as B_0 and B, respectively. The standard curve was constructed by plotting the B/B_0 ratios against the logarithm of different BAP concentrations. Each spiked concentration of the standard solutions was



Fig. 1 The structure chart and principle of FM-LFIA test strip. When there was no BAP in the specimens (negative), FM-mAb conjugates moved along the NC membrane by capillary and were captured by BAP immobilized on the T line, which had the highest intensity of fluorescence. Once the specimens contain BAP (positive), BAP would react with FM-mAb conjugates in the ELISA well. Later, the un-reacted FM-mAb conjugates were captured by BAP immobilized on the T line, which had decreasing fluorescence intensity with increasing concentration of BAP.

performed in triplicate. LOD was defined as the concentration of BAP which was based on the average $\rm FI_T/FI_C$ of negative samples minus threefold standard deviations from the average.³⁹

2.9 Specificity of the FM-LFIA test strip

The specificity was studied using BAP, IALP, PALP, PA, HGB, and ALB in a concentration of 500 ng mL⁻¹. Each measurement was performed in triplicate.

2.10 Accuracy and precision analysis

The accuracy and precision of the FM-LFIA were evaluated by analyzing the recovery and CVs of the intra- and inter-assays with adding three concentrations (5, 50, and 150 ng mL⁻¹) of BAP to the artificial serum. The intra-assays were completed as follows: three concentrations (5, 50, and 150 ng mL⁻¹) of BAP were tested on the same batches of FM-LFIA test strips within 1 day, each concentration of BAP was repeated 3 times. The interassays were analyzed as follows: three concentrations (5, 50, and 150 ng mL⁻¹) of BAP were tested on 3 batches of FM-LFIA test strips within 3 day, each concentration of BAP was repeated 3 times on each batch. The CVs of intra- and inter-assays were calculated.

2.11 Accelerated aging test at 60 $^{\circ}C$

The prepared strips were placed in a drying oven at 60 $^{\circ}$ C for 13 days. FI_T, FI_C, and FI_T/FI_C ratio values of these test strips were recorded every day. Each measurement was performed in triplicate.

3. Results and discussion

3.1 Screening the optimal anti-BAP antibody

The binding affinity between BAP and six anti-BAP antibodies of different concentration was measured by BLI using a BLItz® System. The sensorgram curves are shown in Fig. 2, and the $K_{\rm D}$ was calculated as the K_{on} divided by the K_{off} (Table 1). In Fig. 2, the signal of interference was enhanced with the increasing concentrations (3, 6, 12, 25, and 50 μ g mL⁻¹) of the anti-BAP antibody. The antibodies showed different binding affinities to BAP. The maximal association constant ($K_{\rm on} = 3.17 \times 10^4$ M^{-1} s⁻¹) was found between BAP and anti-BAP antibody (ab17272). The minimum dissociation constant ($K_{
m off} = 3.048 imes$ 10^{-4} s⁻¹) of anti-BAP antibody (11B) is shown in Table 1. Although the dissociation constant ($K_{\text{off}} = 4.765 \times 10^{-4} \text{ s}^{-1}$) of ab17272 was higher than that of 11B, the calculated $K_{\rm D}$ ($K_{\rm D}$ = 1.503×10^{-8} M) of ab17272 was still the minimum among the six anti-BAP antibodies. These data indicated that ab17272 with the minimum $K_{\rm D}$ possesses the highest affinity towards BAP. The antibody with high affinity could efficiently capture BAP and maintain a stable BAP-Ab complex. In the competitive assay, only one antibody was required, the anti-BAP antibody possessing highest binding affinity with BAP should be used for immunization to achieve a higher competitive inhibition ratio.40,41 Compared with other anti-BAP antibodies, the ab17272 exhibited the minimum $K_{\rm D}$. Therefore, the anti-BAP mAb (ab17272) was selected for the FM-LFIA.

3.2 Characterization of FMs and FM-mAb conjugates

It was a key factor in FM-LFIA whether anti-BAP mAb was successfully coupled on the FMs surface. Fluorescence Spectra and UV-vis absorption spectra were often used as the



Fig. 2 Sensorgram for the interaction between six anti-BAP antibodies and BAP. The sensorgram obtained *via* BLI with increasing concentrations (6, 12, 25, and 50 μ g mL⁻¹) of six anti-BAP antibodies including (A) ab17272, (B) 0578G, (C) 11B, (D) ab68716, (E) 55816, and (F) Tu3.

Table 1 Characterization of K_D values for BAP and different anti-BAP Abs using BLItz® system

Antibody	$K_{\mathrm{on}} \left(\mathrm{M}^{-1} \mathrm{s}^{-1} \right)$	$K_{ m off}\left({ m s}^{-1} ight)$	$K_{\mathrm{D}}\left(\mathrm{M} ight)$	
ab17272	$3.17 imes10^4$	4.765×10^{-4}	$1.503 imes10^-$	
0578G	4.592×10^3	5.345×10^{-4}	$1.164 imes10^-$	
11B	6.001×10^3	3.048×10^{-4}	$5.079 imes10^-$	
ab68716	$3.794 imes10^3$	7.235×10^{-4}	$1.907 imes10^-$	
55816	$4.334 imes10^3$	$5.912 imes10^{-4}$	$1.364 imes10^-$	
Tu3	3.878×10^3	9.297×10^{-4}	$2.397 imes10^-$	

characterizing methods to confirm the result of labeling process.⁴² F-380 fluorescence spectrophotometer was used to characterize the fluorescence properties of free FMs and FM-

mAb conjugates. The maximum emission peaks of FM-mAb conjugates and free FMs were observed in a similar position. However, the fluorescence intensities of FM-mAb conjugates decreased compared with those of the FMs alone (Fig. 3A) because a portion of the fluorescence signal was shielded by the antibody on the FM surface. The characteristic absorption peaks of anti-BAP antibody (ab17272), FMs, and FM-mAb conjugates are displayed in Fig. 3B. The spectra of FMs and Anti-BAP mAb had characteristic absorption peaks at 240 and 280 nm, respectively. The spectrum of the FM-mAb conjugate had characteristic absorption peaks at 240 and 280 nm, which confirmed that the antibody (ab17272) was successfully coupled to the FMs.



Fig. 3 (A). Fluorescence intensities of free FMs, anti-BAP mAb and FM-mAb conjugates. (B). Ultraviolet visible spectra of FMs, anti-BAP mAb and FM-mAb conjugates.



Fig. 4 Effects of pH value, the concentration of anti-BAP mAb on labeling process, the volumes of FM-mAb conjugates, and immunoreaction time on the FM-LFIA. (A) Different pH values (5.0, 6.0, 7.0, 8.0, and 9.0), (B) different concentrations of anti-BAP mAb (10, 20, 30, and 50 μ g mg⁻¹), (C) different volumes (1.0, 2.0, and 3.0 μ L) of FMs-mAb conjugates, and (D) immunoreaction dynamics of FI_T/FI_C ratio with different BAP concentrations (0, 5, 30, and 100 ng mL⁻¹) of the sample. Data were obtained from three replicates.

Optimization of experiment conditions 3.3

The labeling pH and concentration of anti-BAP mAb both affect the antibody activity and coupling efficiency in labeling process.43 The optimal labeling pH and concentration of anti-BAP mAb were determined by comparing the FI_T/FI_C ratio of the negative samples and the competitive inhibition ratio of the positive samples. The competitive inhibition ratio was defined as $(1 - B/B_0)$, and the FI_T/FI_C ratios between the negative and positive samples (2.0 ng mL⁻¹) were defined as B_0 and B_1 , respectively. In Fig. 4A, the FI_T/FI_C ratio of negative samples slightly decreased with the increased pH, a strong FI_T/FI_C ratio was observed at pH 6.0. The maximum competitive inhibition ratio (37.53%) of positive samples was also observed at pH 6.0. Therefore, pH 6.0 is the optimal pH for coupling with FMs.44 Similarly, the maximum competitive inhibition ratio (24.21%) of positive samples was obtained at 30 $\mu g mg^{-1}$ of anti-BAP mAb. The FI_T/FI_C ratio of the negative samples gradually increased with the increasing concentrations (10, 20, and 30 μ g mg^{-1}) of anti-BAP mAb, the highest ratio of 0.938 was obtained at 30 μ g mg⁻¹ (Fig. 4B). The FI_T/FI_C ratio of the negative samples decreased at 50 μ g mg⁻¹ compared with that at 30 μ g mg⁻¹, presumably due to the inappropriate ratio between the FMs and anti-BAP mAb. The coupling rate between the FMs and antibody is not always positively correlated with the concentration of antibody. The distance between the antibodies on the surface of FMs narrowed with the increasing concentration of antibody. If the antibodies attached to FMs were excessive, then antibodyantibody interactions cause steric hindrance. Therefore, 30 µg mg^{-1} is the optimal concentration of anti-BAP mAb for coupling with FMs.

In addition, the sensitivity of the FM-LFIA is affected by some other parameters, including the additive amount of FM-mAb conjugates, the concentration of BAP and goat anti-mouse IgG on the T line and C line respectively, and the kinetic reaction time. As shown in Fig. 4C, the highest FI_T/FI_C ratio (0.811) of negative samples was recorded with 2 µL of FM-mAb conjugates. After applying all of the optimized parameters, the reaction time was determined by the samples spiked with different BAP concentrations (0, 5, 30, and 100 ng mL⁻¹). The FI_T/FI_C ratio of different BAP concentrations both gradually decreased with the reaction time and reached a constant value at 15 min after the sample addition (Fig. 4D). Therefore, 15 min of immunoreaction time is required for the FM-LFIA.



Fig. 5 Standard curve for BAP quantitative analysis and fluorescent pictures of the FM-LFIA test strip with a series of spiked concentrations (0.000, 0.005, 0.050, 0.100, 0.500, 5.000, 10.000, 100.000, 250.000, and 500.000 ng mL⁻¹) in artificial serum. (A) The quantitative standard curve was constructed by plotting the B/B_0 ratio against the logarithm of different BAP concentrations. Data were obtained from three replicates. (B) Fluorescent pictures of the FM-LFIA test strip acquired under UV light with different BAP concentrations.

The concentration of BAP on the T line and the goat antimouse IgG on the C line were optimized through the orthogonal experiment with the measurement of positive samples (2.0 ng mL^{-1}) (Table 2). The determination of optimal concentrations of BAP on the T line and goat anti-mouse IgG on the C line were also based on the FI_T/FI_C ratio of the negative samples and the competitive inhibition ratio of the positive samples. As shown in Table 2, the maximum competitive inhibition ratio (41.35%) and high FI_T/FI_C ratio (0.841) were obtained at 2.0 mg mL⁻¹ of BAP on the T line and 0.25 mg mL⁻¹ of goat anti-mouse IgG on the C line, respectively. Therefore, BAP (2.0 mg mL⁻¹)

Table 2 Optimization of the BAP concentration on the T line and the goat anti-mouse IgG concentration on the C line								
Concentration of BAP on the T line (mg mL^{-1})	Concentration of BAP on the C line (mg mL $^{-1}$)	FI_{C}	FI_T	$\mathrm{FI}_{\mathrm{T}}/\mathrm{FI}_{\mathrm{C}}$	Competitive inhibition ratio (%)			
1.0	0.10	256.67	135.44	0.529	12.09			
1.0	0.25	451.33	252.76	0.561	24.45			
1.0	0.50	518.33	251.18	0.485	32.78			
2.0	0.10	247.33	227.95	0.909	22.94			
2.0	0.25	463.00	388.85	0.841	41.35			
2.0	0.50	533.00	317.08	0.594	34.54			
4.0	0.10	240.33	220.00	0.915	19.49			
4.0	0.25	488.22	328.57	0.673	38.64			
4.0	0.50	499.00	246.05	0.493	26.32			

Т

Table 3 The accuracy and precision of the FM-LFIA in BAP-spiked artificial serum

BAP (ng mL ^{-1})	Intra-assay				Inter-assay			
	Mean (ng m L^{-1})	Recovery (%)	SD	CV (%)	Mean (ng mL ^{-1})	Recovery (%)	SD	CV (%)
5	4.9	98.6	0.33	6.7	5.6	111.5	0.26	4.6
50	51.9	103.8	3.84	7.4	50.7	101.3	4.72	9.3
150	151.1	100.7	12.84	8.5	138.6	92.4	9.98	7.2

and goat anti-mouse IgG $(0.25 \text{ mg mL}^{-1})$ were sprayed onto the NC membrane as the T line and C line, respectively.

3.4 Quantitative standard curve of the FM-LFIA test strip

The relationships between the fluorescence intensity and the concentration of BAP were investigated under the optimized conditions. As shown in Fig. 5A, the B/B_0 had a good linear relationship with the BAP concentrations between 0.1 ng mL⁻¹ and 250.0 ng mL⁻¹. The regression equation could be matched as: y = -0.231 lg(x) + 0.587, $R^2 = 0.991$, where y is the competitive inhibition ratio, x is the concentration of BAP and R is the regression coefficient. The calculated LOD was 0.1 ng mL⁻¹. Fig. 5B showed that the FM-LFIA test strip was placed under a UV-light with the excitation wavelength of 470 nm. The picture indicated that fluorescence intensity on the T line changing from strong to weak with increasing concentration of BAP. However the FM-LFIA test strip could not be observed directly by naked eye without a UV-light.

3.5 Specificity for BAP detection

BAP, IALP, PALP, PA, HGB, and ALB were investigated *via* a comparison of results of competitive inhibition ratio at the same concentration of 500 ng mL⁻¹ to evaluate the specificity of BAP detection. As demonstrated in Fig. S2,† top to 96.7% of the competitive inhibition ratio was observed in the presence of BAP, whereas IALP, PALP, PA, HGB, and ALB showed lower competitive inhibition ratio compared with BAP. Thus, the results indicated the good specificity of the FM-LFIA for BAP.

3.6 Accuracy and precision analysis

Recovery experiments were conducted to evaluate the accuracy and precision of the FM-LFIA by using BAP-spiked artificial serum samples. The recovery and CVs of the intra- and interassay are shown in Table 3. The average recoveries for intraand inter-assays ranged from 98.6% to 103.8% and 92.4% to 111.5% with corresponding CVs of 6.7% to 8.5% and 4.6% to 9.3%, respectively.

3.7 Stability analysis of strips in the accelerated aging test

Accelerated aging test was conducted at 60 °C for 13 days to evaluate the stability of the test strip (Fig. S3[†]). Research has proven that the accelerated aging test could estimate the stability of the LFIA test strip.⁴⁵ According to the empirical Arrhenius equation ($K = A \times e^{-E_a/RT}$), the stability of fluorescent signals in 25 °C for one year is equivalent to that in 60 °C for 3

days.⁴⁶ The FI_T/FI_C ratio of different concentrations of BAP did not significantly vary in the accelerated aging test at 60 °C for the first 6 days (Fig. S3†). Therefore, the test strips stored at 25 °C for 1 year can still be used for the detection of BAP.

4. Conclusion

A novel competitive FM-LFIA was constructed for rapid (15 min), sensitive, and quantitative detection of BAP. The optimal anti-BAP antibody with highest binding affinity to BAP was used for the detection of BAP. The FM-LFIA shows high sensitivity that was derived from the fluorescence detection technique and high binding affinity between BAP and anti-BAP Ab. Under optimal conditions, the LOD for the quantitative detection of BAP was 0.1 ng mL⁻¹. The FM-LFIA can be used to detect BAP with better recovery and lower coefficient variation. The average recoveries for intra- and inter-assays ranged from 98.6% to 103.8% and 92.4% to 111.5% respectively, and the CVs for intraand inter-assay were below 10%. The FM-LFIA test strip had good specificity for the detection of BAP and could still be used to detect the BAP when they were stored 25 °C for one year. The method for measurement of BAP is highly recommended for portable and rapid on-site detection in Point of Care Test application.

Acknowledgements

This study was financially supported by the Open Project Program of State Key Laboratory of Food Science and Technology of Nanchang University (SKLF-KF-201616) and the Free Explore Issue of State Key Laboratory of Food Science and Technology of Nanchang University (SKLF-ZZA-201612).

References

- 1 H. E. Takahashi, Clin. Calcium, 2011, 21, 520-527.
- 2 M. C. de Vernejoul, Drugs Aging, 1998, 12, 9-14.
- 3 H. Rief, G. Omlor, M. Akbar, T. Bruckner, S. Rieken, R. Förster, *et al.*, *BMC Cancer*, 2016, **16**, 1–7.
- 4 F. H. Glorieux, L. M. Ward, F. Rauch, L. Lalic, P. J. Roughley and R. Travers, *J. Bone Miner. Res.*, 2002, **17**, 30–38.
- 5 L. M. Ward, F. Rauch, R. Travers, G. Chabot, E. M. Azouz, L. Lalic, *et al.*, *Bone*, 2002, **31**, 12–18.
- 6 M. Zacharin and T. Cundy, J. Pediatr., 2000, 137, 410-415.
- 7 F. Rauch, R. Travers, M. E. Norman, A. Taylor, A. M. Parfitt and F. H. Glorieux, *J. Bone Miner. Res.*, 2000, 15, 957–963.

- 8 K. Mukaiyama, M. Kamimura, S. Uchiyama, S. Ikegami, Y. Nakamura and H. Kato, *Aging: Clin. Exp. Res.*, 2015, 27, 413–418.
- 9 G. Çetin, A. E. Eşkazan, M. C. Ar, Ş. Ö. Aydın, B. Ferhanoğlu,
 T. Soysal, *et al.*, *Turk. J. Chem.*, 2014, 31, 374–380.
- 10 W.-X. Du, S.-F. Duan, J.-J. Chen, J.-F. Huang, L.-M. Yin and P.-J. Tong, *J. Cancer Res. Ther.*, 2014, **10**, 140–143.
- E. Ishimura, S. Okuno, H. Okazaki, K. Norimine, K. Yamakawa, T. Yamakawa, *et al.*, *Kidney Blood Pressure Res.*, 2014, **39**, 299–307.
- 12 J. Allgrove, J. Paediatr. Child Health, 2011, 5, 187–193.
- 13 K. J. Martin and E. A. González, *J. Am. Soc. Nephrol.*, 2007, **18**, 875–885.
- 14 J. M. Roudsari and S. Mahjoub, *Caspian J. Intern. Med.*, 2012, 3, 478–483.
- 15 S. Mahjoub and J. M. Roudsari, *J. Babol Univ. Med. Sci.*, 2006, **8**, 34–39.
- 16 M. T. Parviainen, J. H. Galloway, J. H. Towers and J. A. Kanis, *Clin. Chem.*, 1988, **34**, 2406.
- 17 S. K. Hartwell, D. Somprayoon, P. Kongtawelert, S. Ongchai,O. Arppornchayanon, L. Ganranoo, *et al.*, *Anal. Chim. Acta*, 2007, 600, 188–193.
- 18 F. Ahmed and S. M. Gibbons, *J. Clin. Pathol.*, 2015, **68**, 246–248.
- 19 T. Peng, F. S. Zhang, W. C. Yang, D. X. Li, Y. Chen, Y. H. Xiong, et al., J. Food Prot., 2014, 77, 1824–1829.
- 20 J. H. W. Leuvering, P. J. H. M. Thal, M. V. D. Waart and A. H. W. M. Schuurs, *J. Immunol. Methods*, 1981, 45, 183–194.
- 21 Z. Wang, H. Li, C. Li, Q. Yu, J. Shen and S. S. De, *J. Agric. Food Chem.*, 2014, **62**, 6294–6298.
- 22 K. Hua, C. Xing, C. Hao, L. Liu, L. Wang and C. Xu, *Sensors*, 2013, **13**, 4214–4224.
- 23 J. Y. Wang, M. H. Chen, Z. C. Sheng, D. F. Liu, S. S. Wu and
 W. H. Lai, *RSC Adv.*, 2015, 5, 62300–62305.
- 24 X. Cui, Y. Huang, J. Wang, L. Zhang, Y. Rong, W. Lai, et al., RSC Adv., 2015, 5, 45092–45097.
- 25 D. Quesadagonzález and A. Merkoçi, *Biosens. Bioelectron.*, 2015, **73**, 47–63.
- 26 D. Liu, Z. Yu, Y. Huang, S. Wang, J. Wang, Q. Guo, et al., J. Nanosci. Nanotechnol., 2016, 16, 2291–2595.
- 27 X. Zhang, J. Zhou, C. Zhang, D. Zhang and X. Su, *RSC Adv.*, 2015, **6**, 1279–1287.

- 28 A. Foubert, N. V. Beloglazova and S. S. De, *Anal. Chim. Acta*, 2016, **955**, 48–57.
- 29 Y. Zhao, C. Zhou, R. Wu, L. Li, H. Shen and L. Li, *RSC Adv.*, 2014, 5, 5988–5995.
- 30 L. M. Hu, K. Luo, J. Xia, G. M. Xu, C. H. Wu, J. J. Han, et al., Biosens. Bioelectron., 2017, 91, 95–103.
- 31 X. Zhang, K. Wen, Z. Wang, H. Jiang, R. C. Beier and J. Shen, *Food Control*, 2016, **60**, 588–595.
- 32 S. Nankoberanyi, G. W. Mbogo, N. P. Leclair, M. D. Conrad,
 P. Tumwebaze, S. Tukwasibwe, *et al.*, *Malar. J.*, 2014, 13, 95–100.
- 33 J. L. Wilson, I. M. Scott and J. L. McMurry, *Biochem. Mol. Biol. Educ.*, 2010, 38, 400–407.
- 34 A. Mechaly, H. Cohen, O. Cohen and O. Mazor, Anal. Biochem., 2016, 506, 22–27.
- 35 C. A. Wartchow, F. Podlaski, S. Li, K. Rowan, X. Zhang, D. Mark, et al., J. Comput.-Aided Mater. Des., 2011, 25, 669– 676.
- 36 Y. Yang, C. Li, W. Wang, T. Dong, Y. Xiong, J. Shen, et al., Anal. Methods, 2015, 7, 8683–8688.
- 37 S. L. Deng, S. Shan, C. L. Xu, D. F. Liu, Y. H. Xiong, H. Wei, et al., J. Food Prot., 2014, 77, 1998–2003.
- 38 Q.-Y. Xie, Y.-H. Wu, Q.-R. Xiong, H.-Y. Xu, Y.-H. Xiong, K. Liu, et al., Biosens. Bioelectron., 2014, 54, 262–265.
- 39 L. Anfossi, C. Baggiani, C. Giovannoli, F. Biagioli, G. D'Arco and G. Giraudi, *Anal. Chim. Acta*, 2013, 772, 75–80.
- 40 M. Cummins, C. Dogovski, R. Robert, M. Alderton, D. Chong, D. Proll, *et al.*, *Antibodies*, 2014, **3**, 215–231.
- 41 N. P. Tal, R. Ronit, A. Naomi, E. Eyal, A. Ron, Z. Anat, *et al.*, *Toxins*, 2016, **8**, 64–79.
- 42 Y. B. Miao, H. X. Ren, N. Gan, Y. Cao, T. Li and Y. Chen, *Biosens. Bioelectron.*, 2016, **81**, 454–459.
- 43 Y. Chen, Y. Xin, H. Yang, L. Zhang, Y. Zhang, X. Xia, et al., Int. J. Biol. Macromol., 2013, 56, 6–13.
- 44 H. Duan, X. Chen, W. Xu, J. Fu, Y. Xiong and A. Wang, *Talanta*, 2015, **132**, 126–131.
- 45 W. Jawaid, K. Campbell, K. Melville, S. J. Holmes, J. Rice and C. T. Elliott, *Anal. Chem.*, 2015, **87**, 5324–5332.
- 46 Y. Wang, H. Xu, M. Wei, H. Gu, Q. Xu and W. Zhu, *Mater. Sci. Eng.*, *C*, 2009, **29**, 714–718.